# The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

> **NCT06118723** · — · RECRUITING · sponsor: **Jasper Gerritsen** · enrollment: 784 (estimated)

## Conditions studied

- Glioblastoma
- High-grade Glioma
- Glioblastoma, IDH-wildtype
- Glioblastoma, IDH-mutant
- Glioblastoma Multiforme, Adult
- Astrocytoma, Grade IV
- Astrocytoma, Grade III
- Astrocytoma, Malignant
- Brain Neoplasms
- Brain Neoplasm, Primary
- Brain Neoplasms, Adult
- Brain Neoplasm, Malignant

## Interventions

- **PROCEDURE:** Supramaximal resection
- **PROCEDURE:** Maximal safe resection

## Key facts

- **NCT ID:** NCT06118723
- **Lead sponsor:** Jasper Gerritsen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 784 (ESTIMATED)
- **Last updated:** 2024-02-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118723, "The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06118723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*